Abeona Therapeutics
Abeona Therapeutics reported revenue of $6 million in fiscal 2025. Its operating margin was −1,536.9%. Free cash flow was −$84 million. The diluted share count rose 61.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Abeona Therapeutics does
Abeona is a biopharmaceutical company that develops cell and gene therapies for serious genetic diseases. Its one approved product is Zevaskyn, which the FDA approved in April 2025 to treat wounds in children and adults with recessive dystrophic epidermolysis bullosa, a severe inherited skin disease. Zevaskyn is made from a patient's own skin cells, which are modified and grown into sheets that surgeons apply in a single procedure.
The company sells Zevaskyn itself, through a network of qualified treatment centers chosen for their experience with cell and gene therapy. It makes the product at its own factory in Cleveland, Ohio. It says it may seek partners for Zevaskyn and for other products.
Abeona also researches gene therapies for eye diseases, using a new type of viral delivery vehicle, called a capsid, that it licenses. These are still in development and need FDA approval before they can be sold.
Its biggest risks, as it describes them
- Its income depends on one product, Zevaskyn, and the company has little experience selling a product.
- It may struggle to make Zevaskyn or to line up enough qualified treatment centers to give it.
- Clinical studies of its other therapies may be delayed or fail to show they are safe and work.
- Rules for cell and gene therapies are changing and could make approval harder or slower.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 51 | 52 | 53 | 98 | 191 |
| Debt incl. finance leases | — | — | — | 19 | 20 |
| Net debt (negative means net cash) | — | — | — | −79 | −171 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.4x | 0.1x |
| Interest coverage | −24.6x | −69.2x | −112.8x | −15.3x | −23.9x |
| Current ratio | 3.4x | 6.8x | 4.2x | 6.1x | 6.9x |
| Quick ratio | 3.4x | 6.8x | 4.2x | 6.1x | 6.7x |
Cash flow
Projections
Project Abeona Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Abeona Therapeutics shares on the open market, and 9 insiders sold $3.5 million, $673,790 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Vishwas SeshadriChief Executive Officer, Director | Sold | 19,608 | $5.16 | $101,177 | Form 4 |
| Sep 29, 2026 | Joseph Walter VazzanoChief Financial Officer | Sold | 9,191 | $5.16 | $47,426 | Form 4 |
| Sep 29, 2026 | Brendan M. O'MalleySVP, Chief Legal Officer | Sold | 6,727 | $5.16 | $34,711 | Form 4 |
| Sep 29, 2026 | Madhav VasanthavadaChief Commercial Officer | Sold | 4,902 | $5.16 | $25,294 | Form 4 |
| Sep 1, 2026 | Mark AlvinoDirector | Sold | 15,000 | $5.86 | $87,900 | Form 4 |
| Jul 21, 2026 | Joseph Walter VazzanoChief Financial Officer | Sold | 1,478 | $6.53 | $9,651 | Form 4 |
| Jul 9, 2026 | Vishwas SeshadriChief Executive Officer, Director | Sold | 67,971 | $6.96 | $473,078 | Form 4 |
| Jul 9, 2026 | Joseph Walter VazzanoChief Financial Officer | Sold | 24,880 | $6.96 | $173,165 | Form 4 |
| Jul 9, 2026 | Madhav VasanthavadaChief Commercial Officer | Sold | 12,606 | $6.96 | $87,738 | Form 4 |
| Jul 9, 2026 | Brendan M. O'MalleySVP, Chief Legal Officer | Sold | 12,050 | $6.96 | $83,868 | Form 4 |
| Jun 30, 2026 | Leila AllandDirector | Sold | 11,000 | $5.92 | $65,120 | Form 4 |
| Jun 15, 2026 | Christine Berni SilversteinDirector | Sold | 18,160 | $5.71 | $103,694 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −919.3% | — | — |
| Altman Z'' | −38.47 | −22.51 | −5.75 |
| Accruals ratio | −26.8% | −8.9% | 89.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | — | — |
| F-score | — | — | — |
Compare
Put Abeona Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | |
| DBV Technologies | FY25 | 35.8% | −2,609.2% | −2,159.6% | — | — | — | Compare |
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | Compare |
| Cerenome | FY25 | −10.5% | −293.5% | −399.8% | — | — | — | Compare |
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 1 | 3 | — | 10 | 3 | 1 | 4 | — | 6 |
| Revenue growth | −14.5% | −5.8% | 258.2% | — | — | −70.0% | −52.9% | 147.5% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | 4 |
| Research and development | 11 | 17 | 39 | 49 | 30 | 39 | 29 | 31 | 34 | 27 |
| Operating income | −24 | −28 | −58 | −77 | −81 | −90 | −51 | −47 | −64 | −89 |
| Net income | −22 | −27 | −57 | −76 | −84 | −85 | −40 | −54 | −64 | 71 |
| Diluted EPS (US$) | −16.00 | −16.50 | −29.75 | −37.75 | −22.75 | −21.50 | −5.53 | −2.53 | −1.55 | 1.01 |
| Diluted shares (millions) | 1 | 2 | 2 | 2 | 4 | 4 | 8 | 21 | 41 | 66 |
| Cash flow | ||||||||||
| Cash from operations | −13 | −23 | −39 | −63 | −35 | −66 | −44 | −37 | −56 | −76 |
| Capital expenditure | 0 | 1 | 9 | 6 | 1 | 4 | 0 | 0 | 2 | 8 |
| Free cash flow | −14 | −24 | −48 | −69 | −36 | −70 | −44 | −37 | −58 | −84 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 5 | 8 | 7 | 6 | 9 | 3 | 5 | 7 | 11 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 69 | 138 | 85 | 129 | 95 | 51 | 52 | 53 | 98 | 191 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 19 | 20 |
| Total assets | 111 | 179 | 174 | 223 | 151 | 80 | 64 | 64 | 109 | 220 |
| Total liabilities | 12 | 9 | 40 | 45 | 49 | 37 | 38 | 49 | 65 | 60 |
| Shareholders' equity | 99 | 170 | 134 | 178 | 103 | 42 | 27 | 15 | 44 | 159 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | 73.7% |
| Operating margin | −2,686.3% | −3,325.7% | −1,940.2% | — | −814.2% | −2,994.5% | −3,600.8% | −1,346.7% | — | −1,536.9% |
| Net margin | −2,460.4% | −3,263.9% | −1,890.3% | — | −842.3% | −2,831.2% | −2,807.4% | −1,548.2% | — | 1,223.1% |
| Free cash flow margin | −1,522.3% | −2,809.4% | −1,612.9% | — | −363.6% | −2,327.2% | −3,084.4% | −1,066.9% | — | −1,448.5% |
| Rule of 40 (growth + FCF margin) | −1,536.8% | −2,815.3% | −1,354.7% | — | — | −2,397.2% | −3,137.2% | −919.3% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −26.2% | −20.3% | −37.3% | −48.8% | −60.0% | −117.2% | −114.8% | −260.6% | −216.6% | 70.0% |
| Return on assets | −22.9% | −18.9% | −32.1% | −38.4% | −45.0% | −73.6% | −55.2% | −84.5% | −73.7% | 43.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |